The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers for Disease Control and Prevention (CDC) released a safety notice on May 9 ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Chikungunya isn't prevalent in the U.S., but travelers are being told to be cautious about getting the vaccine for the ...

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

The Trump administration's FDA and CDC is advising U.S. patients using the drug Ixchiq to hold off while U.S. health ...

(Reuters) -The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...